THROMBOSIS – COMPREHENSIVE 30-
MARK ESSAY
(Includes endothelial injury, abnormal blood flow, hypercoagulability, inherited & acquired
thrombophilia, HIT syndrome, Virchow triad, mechanisms, examples, and clinical relevance)
1. Introduction to Thrombosis
Thrombosis refers to the pathologic formation of a blood clot (thrombus) within an intact
vessel or within the heart. It is a major cause of death worldwide because it underlies:
Myocardial infarction
Ischemic stroke
Deep vein thrombosis
Pulmonary embolism
Thrombosis results from a combination of three primary abnormalities, collectively known
as the Virchow Triad:
1. Endothelial injury
2. Abnormal blood flow (stasis or turbulence)
3. Hypercoagulability of blood
These factors may act independently or synergistically to produce thrombosis.
2. The Virchow Triad (Detailed
Explanation)
2.1 Endothelial Injury
Endothelial injury is the most important factor in arterial and cardiac thrombosis because
high flow requires strong procoagulant triggers for clot formation.
A. Types of Endothelial Injury
1. Physical disruption → exposes:
o Subendothelial collagen
o von Willebrand factor (vWF)
oTissue factor
→ Immediate platelet adhesion and activation.
2. Functional injury (Endothelial activation/dysfunction)
Even without physical breaks, endothelial cells can shift to a prothrombotic
phenotype due to:
Inflammation
Cytokines
Hypercholesterolemia
Homocystinemia
Smoking toxins
High shear stress
Infectious agents
B. Prothrombotic Changes in Activated Endothelium
Activated endothelial cells show:
1. Procoagulant changes
↓ Thrombomodulin, which normally inactivates thrombin → thrombin remains
active.
↓ Protein C and TFPI (Tissue Factor Pathway Inhibitor) → ↑ clotting.
↑ Tissue factor expression during inflammation.
2. Antifibrinolytic changes
↑ PAI (Plasminogen Activator Inhibitors) → suppress fibrinolysis.
↓ t-PA (tissue plasminogen activator) → reduced dissolution of fibrin.
C. Clinical Conditions Where Endothelial Injury Occurs
Atherosclerosis (ulcerated plaques expose tissue factor)
Hypertension (shear stress)
Hyperlipidemia
Vasculitis (immune-mediated injury)
Diseases with high homocysteine levels
2.2 Abnormal Blood Flow
Normal blood flow is laminar, where blood cells flow centrally, avoiding contact with the
endothelium.
A. Types
1. Turbulence
2. Stasis
B. How Abnormal Flow Promotes Thrombosis
Both stasis and turbulence:
1. Cause endothelial activation/damage
o Flow disturbance causes increased expression of adhesion molecules & tissue
factor.
2. Disrupt laminar flow
o Platelets and leukocytes move closer to the vessel wall.
3. Prevent dilution of activated clotting factors
o Allows accumulation of thrombin.
4. Prevent inflow of anticoagulant factors
o Such as antithrombin in fresh plasma.
5. Reduce blood clearance of procoagulant particles
o Microparticles remain in contact with vessel wall.
C. Clinical Examples
1. Turbulence
Atherosclerotic plaques (surface irregularity → turbulence)
Vessel narrowing due to plaque
Post-stenotic dilation
2. Stasis
Most important for venous thrombosis.
Examples:
Prolonged immobilization (bed rest, long travel)
Congestive heart failure
Atrial fibrillation → left atrial stasis
Aneurysms → local pooling
Hyperviscosity (polycythemia vera)
Sickle cell disease → obstructed microcirculation
2.3 Hypercoagulability
Hypercoagulability refers to any abnormality of blood that increases the tendency to clot.
Two types:
1. Primary (genetic / inherited)
2. Secondary (acquired)
3. Primary (Inherited) Hypercoagulability
3.1 Factor V Leiden Mutation
Most common inherited thrombophilia.
Mutation renders Factor V resistant to inactivation by Protein C.
Leads to persistent thrombin generation.
Prevalence: 2–15% in Caucasians.
Found in up to 60% of recurrent DVT cases.
Risk Levels
Heterozygotes: 5-fold ↑ risk
Homozygotes: 50-fold ↑ risk
3.2 Prothrombin Gene Mutation (G20210A)
Mutation in 3′ UTR → ↑ prothrombin levels.
Prevalence: 1–2%.
3-fold increased risk of venous thrombosis.
3.3 Deficiency of Anticoagulants
Rare but severe:
Antithrombin III deficiency
Protein C deficiency
Protein S deficiency
Clinical Features
Recurrent venous thrombosis
Occurs at a young age (teenage/young adults)
Leads to recurrent thromboembolism
3.4 Homocystinemia
Causes
Inherited deficiency of cystathionine β-synthase
Deficiency of vitamins B6, B12, folate
Mechanism
Homocysteine forms thioster linkages with proteins (including fibrinogen)
→ Increases prothrombotic activity
→ Promotes endothelial injury
4. Secondary (Acquired)
Hypercoagulability
Acquired forms are more common and often multifactorial.
4.1 Important Causes
A. Prolonged immobilization
Stasis is the major mechanism.
B. Cancer (Disseminated malignancy)
Tumor cells release procoagulants
Strongly promotes venous thrombosis
C. Advancing age
Decreased endothelial PGI₂ (prostacyclin) → increased platelet aggregation.
D. Smoking
Mechanism unclear; may cause endothelial dysfunction.
E. Obesity
Increased systemic inflammation
Unknown mechanisms promoting hypercoagulability
F. Pregnancy & Oral Contraceptive Pills
↑ Hepatic synthesis of coagulation factors
↓ Synthesis of anticoagulants
↓ venous return (pregnancy → mechanical pressure)
G. Heparin-Induced Thrombocytopenia (HIT)
(Discussed in detail later)
H. Antiphospholipid Antibody Syndrome
Autoantibodies cause arterial & venous thrombosis
5. Heparin-Induced Thrombocytopenia
(HIT) Syndrome
HIT is a life-threatening complication seen mainly with unfractionated heparin.
5.1 Mechanism (Step-by-Step)
1. Heparin binds to PF4, released from platelet alpha granules.
2. The PF4–heparin complex forms a neoantigen.
3. Body forms IgG antibodies against this complex.
4. PF4-IgG-heparin complexes attach to platelet Fc receptors.
5. This causes:
o Platelet activation
o Aggregation
o Release of more PF4 → amplifying loop
6. Activated platelets release procoagulant microparticles.
Result
Thrombocytopenia due to platelet consumption
Thrombosis, paradoxically, because of platelet activation
Clots may occur in:
o Veins
o Arteries
o Microvasculature
Clinical Consequences
DVT
Pulmonary embolism
Limb gangrene
Myocardial infarction
Stroke
6. Clinical Consequences of Thrombosis
6.1 Arterial Thrombosis
Usually superimposed on atherosclerosis.
Myocardial infarction
Stroke
Peripheral arterial occlusion
Composed mainly of platelets due to high-flow conditions.
6.2 Venous Thrombosis (Phlebothrombosis)
Occurs mainly due to stasis.
Deep vein thrombosis (DVT)
Pulmonary embolism
Rich in fibrin and RBCs (“red thrombi”).
6.3 Cardiac Mural Thrombosis
Seen in:
Myocardial infarction (noncontractile myocardium)
Dilated cardiomyopathy
Atrial fibrillation (left atrial appendage thrombus)
6.4 Microvascular Thrombosis
DIC
HIT
Sepsis
Malignancy
7. Conclusion
Thrombosis is a key pathology resulting from the interplay of:
1. Endothelial injury
2. Abnormal blood flow (stasis/turbulence)
3. Hypercoagulability (inherited/acquired)
Inherited mutations like Factor V Leiden and prothrombin G20210A, and acquired states
like HIT, cancer, immobility, OCP use, pregnancy, and advanced age significantly elevate
thrombotic risk. Understanding these mechanisms is essential for diagnosis, prevention, and
targeted therapy.